Safety and Efficacy of (PN-152,243)/PN-196,444 in the Prevention of Thrombocytopenia
Public ClinicalTrials.gov record NCT00039910. Field values are reproduced from the official study page; the official ClinicalTrials.gov record remains the source of truth for eligibility, enrollment, and contact information.
All trial information on this site comes from the official ClinicalTrials.gov public API (clinicaltrials.gov/api/v2), run by the U.S. National Library of Medicine. We only display that public information; we do not add opinions, endorsements, or any other intent. Always review the official ClinicalTrials.gov record for the latest information.
Official title
Safety and Efficacy of (PN-152,243)/PN-196,444 in the Prevention of Thrombocytopenia in Recurrent or Refractory Non-Burkitt's, Non-Hodgkin's Lymphoma (NHL) or Hodgkin's Disease Receiving DHAP (Dexamethasone, High-Dose Cytarabine and Cisplatin) Chemotherapy
Brief summary
Reproduced verbatim from the official ClinicalTrials.gov record. Not medical advice.
Intensive chemotherapy is associated with significant thrombocytopenia, often requiring platelet transfusion to maintain platelet counts. This investigational drug has been demonstrated to increase platelet counts. This study will test the safety and efficacy of the investigational drug in the prevention of thrombocytopenia in patients with recurrent or refractory intermediate-grade or high-grade non-Burkitt's, non-Hodgkin's lymphoma (NHL), or Hodgkin's disease receiving DHAP (Dexamethasone, high-dose Cytarabine, and Cisplatin) chemotherapy.
Study identification
- NCT ID
- NCT00039910
- Recruitment status
- Completed
- Study type
- Interventional
- Phase
- Phase 3
- Enrollment
- 240 participants
Conditions and interventions
Conditions
Eligibility (public fields only)
- Age range
- 18 Years and older
- Sex
- All
- Healthy volunteers
- Healthy volunteers not accepted
This page does not interpret eligibility. Detailed inclusion and exclusion criteria are on the official ClinicalTrials.gov record.
Study timeline
- Start date
- Jul 2000 (Type not available)
- Primary completion
- Not listed
- Completion
- Mar 2003 (Actual)
- Last update posted
- May 4, 2007
2000 – 2003
United States locations
- U.S. sites
- 27
- U.S. states
- 14
- U.S. cities
- 21
| Facility | City | State | ZIP | Site status |
|---|---|---|---|---|
| Pfizer Investigational Site | Phoenix | Arizona | 85023 | — |
| Pfizer Investigational Site | La Jolla | California | 92037 | — |
| Pfizer Investigational Site | Loma Linda | California | 92354 | — |
| Pfizer Investigational Site | Los Angeles | California | 90033-0804 | — |
| Pfizer Investigational Site | Los Angeles | California | 90036 | — |
| Pfizer Investigational Site | Los Angeles | California | 90048 | — |
| Pfizer Investigational Site | Los Angeles | California | 90089 | — |
| Pfizer Investigational Site | Orange | California | 92868 | — |
| Pfizer Investigational Site | Tamarac | Florida | 33321 | — |
| Pfizer Investigational Site | Chicago | Illinois | 60637 | — |
| Pfizer Investigational Site | Chicago | Illinois | 60640 | — |
| Pfizer Investigational Site | Lake Charles | Louisiana | 70601 | — |
| Pfizer Investigational Site | Detroit | Michigan | 48202 | — |
| Pfizer Investigational Site | Saint Joseph | Michigan | 49085 | — |
| Pfizer Investigational Site | Southfield | Michigan | 48076 | — |
| Pfizer Investigational Site | Jefferson City | Missouri | 65109 | — |
| Pfizer Investigational Site | Jefferson City | Missouri | 90048 | — |
| Pfizer Investigational Site | Omaha | Nebraska | 68198 | — |
| Pfizer Investigational Site | Brooklyn | New York | 11235 | — |
| Pfizer Investigational Site | Durham | North Carolina | 27705 | — |
| Pfizer Investigational Site | Coos Bay | Oregon | 97420 | — |
| Pfizer Investigational Site | Hershey | Pennsylvania | 17033 | — |
| Pfizer Investigational Site | Bristol | Tennessee | 37620 | — |
| Pfizer Investigational Site | Abingdon | Virginia | 24210 | — |
| Pfizer Investigational Site | Abingdon | Virginia | 24211 | — |
| Pfizer Investigational Site | Lebanon | Virginia | 24266 | — |
| Pfizer Investigational Site | Marion | Virginia | 24354 | — |
Site contact phone numbers, emails, and investigator names are intentionally not displayed here. Open the official ClinicalTrials.gov record for site contact information.
Non-U.S. locations
This page focuses on the U.S. directory. The official record also lists 11 non-U.S. sites.
About this trial record page
- What this page shows
- Public field values for ClinicalTrials.gov record NCT00039910, including study identification, conditions, interventions, eligibility (age, sex, healthy volunteer), timeline, and U.S. site list.
- What this page does not do
- No medical advice, eligibility judgments, treatment recommendations, study quality scoring, or AI-generated medical summaries. No site contact phone numbers, emails, or investigator names.
- Where the data comes from
- Sourced from the official ClinicalTrials.gov public API. The official record is the source of truth.
- Last refresh
- Last update posted May 4, 2007 · Synced Nov 10, 2026
Related: full search, browse by condition, browse by drug or therapy, browse by sponsor, browse by U.S. city.
Open the official record
The complete public registry record, listed eligibility criteria, and available contact information for NCT00039910 live on ClinicalTrials.gov.